معرفی
Jorge Moscat is a Professor and the Homer T. Hirst III Professor of Oncology in the Department of Pathology at Weill Cornell Medical College, where he also serves as Vice-Chair for Experimental Pathology. He is affiliated with the Graduate School of Medical Sciences and the Cell & Developmental Biology PhD program. His research is centered on colorectal cancer, particularly the aggressive mesenchymal (CMS4) subtype, focusing on tumor initiation, therapy resistance, and metastasis.
His research interests include:
- Colorectal cancer (CRC) biology
- Mesenchymal and stem-like tumor phenotypes
- Tumor microenvironment and desmoplastic stroma
- Immunosuppression in cancer
- Mechanisms of preneoplasia initiation
- Liver metastasis
- Role of atypical protein kinase Cs (PKCζ and PKCλ/ι) in tumorigenesis
- Therapy resistance mechanisms
- Stromal activation and extracellular matrix dynamics
Although no publications are listed in the provided text, his lab's work integrates mouse models of serrated tumorigenesis with human tumor datasets to uncover vulnerabilities in aggressive CRC subtypes, particularly CMS4, which accounts for 30% of CRC cases and has poor prognosis.
His major scientific honors include:
- Elected Member of the Academia Europaea (2006)
- Associate Director, University of Cincinnati Cancer Center (2008)
- Associate Director of Basic Research, NCI-Cancer Center SBP Medical Discovery Institute (2015)
- Deputy Director, NCI-Cancer Center SBP Medical Discovery Institute (2017)
- Chair of Tumor Cell Biology Study Section, NCI/NIH (2018)
- Homer T. Hirst III Professor of Oncology (2021)
Jorge Moscat has held significant leadership roles in cancer research, including Chair of the Department of Cancer and Cell Biology at the University of Cincinnati, Director of the Institute for Molecular Biology in Spain, and Deputy Director at Sanford Burnham Prebys. He has received major grants and institutional support to investigate metabolic and signaling pathways in cancer. His lab at Weill Cornell continues to explore novel therapeutic targets in colorectal cancer, with a focus on disrupting tumor-stroma interactions and enhancing immunotherapy efficacy.
He leads a research laboratory investigating mechanisms of intestinal inflammation and cancer, with current projects spanning preneoplasia initiation, stromal activation, and metastatic progression. His team uses genetically engineered mouse models and human tumor analyses to identify key drivers of aggressive CRC.
